Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
PURPOSE: To define the toxicity, imaging, and biodistribution characteristics of iodine 131-labeled monoclonal antibody F19 (131I-mAbF19). MAbF19 recognizes the fibroblast activation protein (FAP), a cell-surface glycoprotein not present in most normal tissues, but abundantly expressed by reactive stromal fibroblasts of epithelial cancers, including more than 95% of primary and metastatic colorectal carcinomas. PATIENTS AND METHODS: 131I-mAbF19 was administered intravenously to 17 patients with hepatic metastases from colorectal carcinoma who were scheduled for resection of localized metastases or insertion of hepatic artery catheter for regional chemotherapy. Seven to 8 days before surgery, patients received 131I-mAbF19 at three dose levels, with at least four patients entered at each level. RESULTS: No toxicity associated with intravenous 131I-mAbF19 administration was observed. Tumor images were obtained on planar and single-photon emission tomography (SPECT) scans in 15 of 17 patients with hepatic metastases, tumor-infiltrated portal lymph nodes, and/or recurrent pelvic disease. The smallest lesion visualized was 1 cm in diameter. The optimal time for tumor imaging was 3 to 5 days after 131I-mAbF19 administration. The use of image registration techniques allowed precise anatomic localization of 131I-mAbF19 accumulation. Immunohistochemical analysis of biopsy tissues showed expression of FAP in the tumor stroma (but not in normal liver) in all patients studied and confirmed that the FAP-positive tumor stromal fibroblasts were interposed between the tumor capillaries and the malignant colon epithelial cells. At the time of surgery, tumor-to-liver ratios up to 21:1 and tumor-to-serum ratios up to 9:1 were obtained. The fraction of the injected 131I-mAbF19 dose per gram tumor (%ID/g tumor) localized to hepatic metastases at the time of surgery ranged from 0.001% to 0.016%. CONCLUSION: The FAP tumor fibroblast antigen is highly expressed in primary and metastatic colorectal carcinomas and shows limited expression in normal adult tissues. This highly selective expression pattern allows imaging of colorectal carcinoma lesions as small as 1 cm in diameter on 131I-mAbF19 scans. Because of the consistent presence of FAP in the stroma of epithelial cancers and the accessibility of FAP-positive tumor stromal fibroblasts to circulating monoclonal antibodies (mAbs), this study suggests possible diagnostic and therapeutic applications of humanized mAbF19 and mAbF19 constructs with novel immune and nonimmune effector functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C., & Chambon, P. (1990) · Nature · doi:10.1038/348699a0 · Cited by 1,131
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 945
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Self-citationRadiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310213291702 · Cited by 644
Delivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and Strategies
Jain, R. K. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.570 · Cited by 557
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Monoclonal Antibodies in Diagnosis and Therapy
Waldmann, T. A. (1991) · Science · doi:10.1126/science.2047874 · Cited by 385
Recombinant Toxins for Cancer Treatment
Pastan, I., & FitzGerald, D. (1991) · Science · doi:10.1126/science.1683495 · Cited by 299
Rettig, W. J., Garin-Chesa, P., Beresford, H. R., Oettgen, H. F., Melamed, M. R., & Old, L. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.9.3110 · Cited by 271
Self-citationVascular attack as a therapeutic strategy for cancer
Denekamp, J. (1990) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046365 · Cited by 264
Rettig, W. J., Garin-Chesa, P., Healey, J. H., Su, S. L., Jaffe, E. A., & Old, L. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10832 · Cited by 242
Self-citationHinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Cullen, K. J., Smith, H. S., Hill, S. M., Rosen, N. X., & Lippman, M. E. (1991) · PubMed · Cited by 219
Dvorak, H. F., Nagy, J. A., & Dvořàk, A. M. (1991) · PubMed · Cited by 203
Rettig, W. J., Garin‐Chesa, P., Healey, J. H., Su, S. L., Ozer, H. L., Schwab, M. G., Albino, A. P., & Old, L. J. (1993) · PubMed · Cited by 188
Self-citationAntibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.
Oosterwijk, E., Bander, N. H., Divgi, C. R., Welt, S., Wakka, J. C., Finn, R. D., Carswell, E. A., Larson, S. M., Warnaar, S. O., & Fleuren, G. J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.738 · Cited by 182
Self-citationRettig, W. J., Erickson, H., Albino, A. P., & Garin‐Chesa, P. (1994) · Journal of Cell Science · doi:10.1242/jcs.107.2.487 · Cited by 119
Self-citationMonoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers
Riethmüller, G., & Johnson, J. P. (1992) · Current Opinion in Immunology · doi:10.1016/0952-7915(92)90041-c · Cited by 118
Rettig, W. J., Chesa, P. G., Beresford, H. R., Feickert, H. J., Jennings, M. T., Cohen, J., Oettgen, H. F., & Old, L. J. (1986) · PubMed · Cited by 116
Self-citationA murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.
Burrows, F. J., Watanabe, Y., & Thorpe, P. E. (1992) · PubMed · Cited by 55
Immunogenetics of cell surface antigens of human cancer
Rettig, W. J. (1992) · Current Opinion in Immunology · doi:10.1016/0952-7915(92)90039-h · Cited by 10
Antibody-Drug Conjugates for Cancer Therapy
Reisfeld, R. A., Mueller, B. M., Schrappe, M., WARGALLA, U., Yang, H. M., & Wrasidlo, W. (1991) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(22)00326-5 · Cited by 6
Cited by
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Self-citationTurning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., Adeberg, S., Rathke, H., Röhrich, M., Winter, H., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227967 · Cited by 1,464
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Lindner, T., Loktev, A., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 935
Metadata
- Authors
- Welt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., & Old, L. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-06
- Volume
- 12
- Issue
- 6
- Pages
- 1193-1203
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1905956901
- Cited by
- 266
- References
- 23
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.